The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.
SGS announced the completion of expansions to its bioanalytical laboratory in Poitiers, France on Sept. 30, 2021. The addition consists of a new 800 m² building that houses additional drug development equipment and extra office space.
Included in the expansion are chromatography and immunoassay laboratories that are intended to dramatically increase production capacity. Additional capacities such as mass spectrometry, immunoanalysis, and cell-based bioassays will be added to the site’s existing capabilities.
The facility also adds new digital tools, such as customer relationship management and configure, price, quote software for contracting and monitoring. A large sample storage combined with bar code systems allows for storage of up to 800,000 samples at a time.
“The expansion comes at an exciting time,” said Walid Elbast, SGS’s general manager in France, in a company press release. “It allows us to meet increased demand in the area and shorten processes for our pharmaceutical clients. For me, this is a testimony to the outstanding teamwork of everyone involved and SGS’s continued investment in supporting innovation in the life sciences sector.”
Source: SGS
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.